Large medical practices evidence limited view of EHR product market

A new survey of 1,400 clinicians has found that a strong majority of medical practices with 26 or more members, some 60 percent, use one of only 10 different EHR products. Among practices with just one to three clinicians, the subset focused on 10 or fewer EHR products was a slim majority, just 51 percent.

The survey was conducted in 2013 and 2014 by AmericanEHR Partners, the supplier of free EHR support founded by the American College of Physicians (ACP) and Cientis Technologies. It showed that the 40 percent of practices using an EHR product other than those in the top 10 spread out among 86 different vendors.

“The key finding is that data shows that larger practices tend to be more focused on the same systems,” ACP executive Shari M. Erickson said in a news release.

The survey report, released May 18, showed the dominant vendors among respondents to be Epic Systems Corporation with 14 percent of the market and Allscripts Healthcare Solutions Inc., with 9 percent. Among the other vendor findings presented:

  • EHR product market share for solo practice showed Practice Fusion Inc. as the product with the largest market share, 15 percent.
  • The EHR product market share for four to 10 clinician practices showed EpicCare Ambulatory EMR as the product with the largest market share, 14 percent.
  • The EHR product market share for practices with 26 or more clinicians also showed EpicCare Ambulatory EMR as the product with the largest market share, 16 percent.

For more on the report, click here

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.